<DOC>
	<DOCNO>NCT01988896</DOCNO>
	<brief_summary>A Phase Ib , open-label , multicenter study design assess safety , tolerability , pharmacokinetics coadministration intravenous ( IV ) dose atezolizumab ( engineer anti-programmed death-ligand 1 [ anti PD-L1 ] antibody ) oral dose cobimetinib participant metastatic locally advanced cancer standard therapy exist .</brief_summary>
	<brief_title>Study Atezolizumab Combination With Cobimetinib Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Informed Consent Form . Solid tumor metastatic , locally advanced recurrent . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy great equal 12 week . Measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) v 1.1 . Adequate hematologic end organ function . Use highly effective contraception . Histological tumor tissue specimen . Participants enrol indicationspecific expansion cohort Stage 2 must consent tumor biopsy must one follow type cancer : Metatastic colorectal cancer Nonsmall cell lung cancer Melanoma . Consent undergo pretreatment and/or ontreatment tumor biopsy biomarker analysis participant biopsymandated cohort . Cancer specific exclusion criterion : Any approved anticancer therapy , include chemotherapy , hormonal therapy within 3 week prior initiation study treatment . Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment . Known active untreated central nervous system ( CNS ) metastases . Leptomeningeal disease . Uncontrolled tumorrelated pain uncontrolled pleural effusion , pericardial effusion , ascites require recurrent ( monthly frequently ) drainage procedure . Uncontrolled hypercalcemia symptomatic hypercalcemia require continue use bisphosphonate therapy denosumab . General medical exclusion criterion : Pregnant lactate woman . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . Known hypersensitivity Chinese hamster ovary cell product . Allergy hypersensitivity component atezolizumab formulation . History autoimmune disease . Participants prior allogeneic stem cell solid organ transplantation . Positive test human immunodeficiency virus ( HIV ) . Participants active hepatitis B , hepatitis C , tuberculosis . Severe infection within 4 week prior Cycle 1 Day 1 . Signs symptoms infection within 2 week prior Cycle 1 Day 1 . Received therapeutic oral IV antibiotic within 2 week prior Cycle 1 Day 1 . Significant cardiovascular disease . Major surgical procedure diagnosis within 28 day prior Cycle 1 Day 1 anticipation need major surgical procedure course study . Administration live , attenuated vaccine within 4 week Cycle 1 Day 1 . Exclusion criterion unique cobimetinib : History prior significant toxicity another mitogenactivated protein kinase ( MEK ) pathway inhibitor require discontinuation treatment . Allergy hypersensitivity component cobimetinib formulation . History congenital long QT syndrome correct QT interval ( QTc ) &gt; 450 millisecond screen . Left ventricular ejection fraction ( LVEF ) institutional low limit normal ( LLN ) 50 % , whichever low , determined echocardiogram Multi Gated Acquisition Scan ( MUGA ) scan . History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , central serous chorioretinopathy ( CSCR ) , retinal vein occlusion ( RVO ) , neovascular macular degeneration . History malabsorption syndrome condition would interfere enteral absorption . Exclusion criterion related medication : Prior treatment cluster differentiation ( CD ) 137 ( CD137 ) agonists immune checkpoint blockade therapy , systemic immunostimulatory agent , systemic immunosuppressive medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>